Abbott India has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to market and distribute ‘Vonoprazan’ in India under the brand name ‘Vonefi’. Vonoprazan (PCAB or Potassium Competitive Acid Blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose.
Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable Abbott, a leader in the gut health space, to enhance access to this novel therapy to more patients across India.
Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: